ResearcherChina Medical UniversityActive in the last 2 years

Tianqi Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0898-2195; OpenAlex author ID A5123249595. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 1 paper

Papers 1

Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. Co-author DOI 10.1038/s42003-026-09538-6 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Feng Li · 1 shared paper, 2026 · strength 0.32
- Paper Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. DOI 10.1038/s42003-026-09538-6 ↗
Xiaodong Tan · 1 shared paper, 2026 · strength 0.32
- Paper Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. DOI 10.1038/s42003-026-09538-6 ↗
Zhongbo Zhang · 1 shared paper, 2026 · strength 0.32
- Paper Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. DOI 10.1038/s42003-026-09538-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.